BIBLIOGRAPHY
  1. White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85(3):560.
  2. Van den Berg HM, De Groot PHG, Fischer K. Phenotypic heterogeneity in severe hemophilia. J Thromb Hemost 2007; 5(s1): 151-156.
  3. Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev 2003; 17(Suppl 1): S1–5.
  4. Walsh PN, Rainsford SG, Biggs R. Platelet coagulant activities and clinical severity in haemophilia, Thromb. Diath. Haemorrh. 29 (1973) 722–729.
  5. Yee DL. Platelets as modifiers of clinical phenotype in hemophilia. Scientific World Journal 6 (2006) 661–668.
  6. Riedl J, Ay C, Pabnger I. Platelets and hemophilia: A review of the literature. Thrombosis Research 155 (2017) 131–139.
  7. McDaniel M. RN (2013). Treatment of Hemophilia A and B. Nursing Working Group–Nurses’ Guide to Bleeding Disorders (chapter 6, pp 1-9). New York, National Hemophilia Foundation.
  8. Lacroix R, Judicone C, Mooberry M, et al. Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop.J Thromb Haemost 2013;10.1111/jth.12207. doi: 10.1111/jth.12207.
  9. Fox SC, May J, Dovaltova N, Glenn JR, Johnson A, White AE, Ashwin Radhakrishnan A, Heptinstall S. How does measurement of platelet P-selectin compare with other methods of measuring platelet function as a means of determining the effectiveness of antiplatelet therapy?. Platelets 2019;30(3):290-295.
  10. Tesfamarian B. Distinct characteristics of neonatal platelet reactivity. Pharmacol. Res 2017; 123:1-9. doi: 10.1016/j.phrs.2017.06.003
  11. Algathani M, Heptinstall S. Novel strategies for assessing platelet reactivity. Future Cardiol. 2017; (1):33-47. doi: 10.2217/fca-2016-0054.
  12. van Bladel ER, Schutgens REG, Fischer K, de Groot PG, Roest M. Platelet degranulation and glycoprotein IIbIIIa opening are not related to bleeding phenotype in severe haemophilia A patients. Thromb Haemost. 2014;111(6):1022–30.
  13. Podda GM, Bucciarelli P, Lussana F, Lecchi A, Cattaneo M. Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time. J Thromb Haemost. 2007;5(12):2393–8.
  14. Hayward CPM, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost. 2006;4(2):312–9.
  15. Grünewald M, Siegemund A, Grünewald A, Konegen A, Koksch M, Griesshammer M. Absence of compensatory platelet activation in patients with severe haemophilia. but evidence for a platelet collagen-activation defect. Platelets. 2002;13(8):451–8.
  16. Wartiovaara-Kautto U, Joutsi-Korhonen L, Ilveskero S, Armstrong E, Lassila R. Platelets significantly modify procoagulant activities in haemophilia A. Haemophilia. 2011;17(5):743–51.
  17. Favaloro EJ, Facey D, Henniker A. Use of a novel platelet function analyzer (PFA-100) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand’s disease and other disorders. Am J Hematol. 1999;62(3):165–74.
  18. Carcao MD, Blanchette VS, Dean JA, et al. The Platelet Function Analyzer (PFA-100): a novel in-vitro system for evaluation of primary haemostasis in children. Br J Haematol. 1998;101(1):70–3.
  19. Fressinaud E, Veyradier A, Truchaud F, et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood. 1998;91(4):1325–31.
  20. Haugaard AK, Lund TT, Birch C, et al. Discrepant coagulation profile in HIV infection: elevated D-dimer but impaired platelet aggregation and clot initiation. AIDS. 2013;27(17):2749–58.
  21. Writters P, Freson K, Verslype C, et al. Review article: blood platelet number and function in chronic liver disease and cirrhosis. Aliment Pharmacol Ther. 2008;27(11):1017–29.
  22. van Bladel ER, Roest M, de Groot PG, Schutgens REG. Up-regulation of platelet activation in hemophilia A. Haematologica. 2011;96(6):888–95.
  23. Wartiovaara-Kautto U, Joutsi-Korhonen L, Ilveskero S, Armstrong E, Lassila R. Platelets significantly modify procoagulant activities in haemophilia A. Haemophilia. 2011;17(5):743–51.
  24. Teyssandier M, Delignat S, Rayes J, et al. Activation state of platelets in experimental severe hemophilia A. Haematologica. 2012;97(7):1115–6.
  25. Ferreiro JL, Sibbing D, Angiolillo DJ. Platelet function testing and risk of bleeding complications. Thromb Haemost. 2010;103(6):1128–35.
  26. Jennings LK, Dockter ME, Wall CD, Fox CF, Kennedy DM. Calcium mobilization in human platelets using indo-1 and flow cytometry. Blood. 1989;74(8):2674–80.
  27. Davies TA, Drotts D, Weil GJ, Simons ER. Flow cytometric measurements of cytoplasmic calcium changes in human platelets. Cytometry. 1988;9(2):138–42.
  28. Owens AP, Mackman N. microvesicles in hemostasis and thrombosis. Circ Res 2011; 108: 1284–97.
  29. Boulanger CM, Dignat-Georges FD. microvesicles: an introduction. Arterioscler Thromb Vasc Biol 2011; 31: 2–3.
  30. Mobarrez F, Mikovic D, Antovic A, Antovic JP. Is a decrease of microvesicles related to improvement of hemostasis after FVIII injection in hemophilia A patients treated on demand? J Thromb Haemost. 2013;11:697–703.
  31. Proulle V, Hugel B, Guillet B, et al. Circulating microvesicles are elevated in haemophiliacs and non-haemophilic individuals aged <18 years. Br J Haematol. 2005;131(4):487–9.
  32. Qin F, Huang S, Li Z, Ye J, Sun J. The Platelet-Derived microvesicles Related to the Clinical Phenotype Heterogeneity of Hemophlia a. Blood. 2014;124(21):2828.
  33. Zhou X, Qin F, Li H, et al. Platelet-Derived microvesicles May Influence Phenotypic Heterogeneity in Patients with Severe Hemophilia. Blood. 2015;126(23):4673.
  34. Artoni A, Santagostino E, Mancuso ME, Lecchi A, Mannuci PM. Microparticle levels are high in patients with Hemophilia A and can be further increased by DDAVP administration. Blood. 2007;110(11):3139.
Figure Legends.
Figure 1. Calcium responses to ADP (A) or TRAP(B) of platelets as measured with Fluo-3 by flow cytometry.
Figure 2. Area under the curve of the calcium responses shown in figure 1.
Figure 3. Platelet function by optical aggregation with PRP (with Chronolog). AUC: area under the curve.
Figure 4. Platelet function by whole blood impedance (with Multiplate). AUC: area under the curve; U: units; UA; arbitrary units.
Figure 5. Platelet function evaluated by flow cytometry. FMI: fluorescence mean intensity.